Video

COVID-19 Pandemic Provides Opportunities to Innovate With Oral Oncolytics, Medically Integrated Dispensing

Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.

In an interview with Pharmacy Times, Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.

In the interview, Stutz and Alwardt discussed the necessity for close monitoring when patients receive oral oncolytics, potential concerns about adherence, and how telemedicine enabled this care and monitoring. Stutz and Alwardt also co-authored an article on the subject, which will be featured in the October issue of Directions in Oncology Pharmacy.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Asthma COPD Breath Nebulizer And Mask Given By Doctor Or Nurse - Image credit: Angelov | stock.adobe.com
Hematology -- Image credit: DIgilife | stock.adobe.com
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com